Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

This early-phase study tests whether therapeutic ultrasound (sound waves directed at the brain to stimulate the immune system) combined with standard treatment can improve outcomes for people with newly diagnosed glioblastoma, the most aggressive type of brain tumor. **You may be eligible if...** - You are 18 or older with a newly diagnosed confirmed glioblastoma (IDH wild-type) - Your tumor lacks a specific protective gene modification (MGMT unmethylated) - You have completed standard radiation therapy, with or without the chemotherapy drug temozolomide - You are in reasonably good physical condition (ECOG 0–2) - You have not previously received immunotherapy for any condition **You may NOT be eligible if...** - Your tumor is in multiple locations or in the back of the brain (posterior fossa) - You have uncontrolled seizures - You have had prior treatment with immune checkpoint drugs - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.